股本结构
单位：万股
| 公告日期 | 2025-11-12 | 2025-08-11 | 2025-05-12 | 2025-05-13 | 2025-03-11 | 2024-11-12 |
|---|---|---|---|---|---|---|
| 证券总股本 | 18468.96 | 18457.07 | 18428.84 | 18402.90 | 18364.92 | 18345.05 |
| 普通股本 | 36937.91 | 36914.14 | 36857.68 | 36805.81 | 36729.83 | 36690.10 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-09-30 | 2025-06-30 | 2025-05-07 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
，当前存托凭证比例为：2
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-11-12 | 36937.91 | 未披露 | 定期报告 | 2025-09-30 |
| 2025-08-11 | 36914.14 | 未披露 | 定期报告 | 2025-06-30 |
| 2025-05-12 | 36857.68 | 未披露 | 定期报告 | 2025-05-07 |
| 2025-05-13 | 36805.81 | 未披露 | 定期报告 | 2025-03-31 |
| 2025-03-11 | 36729.83 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Reclassification of vested restricted share units
|
2024-12-31 |
| 2024-11-12 | 36690.10 | 未披露 |
更多>>
From January 1, 2024 to September 30, 2024
Reclassification of vested restricted share units
|
2024-09-30 |
| 2024-09-20 | 36857.68 | 未披露 | 定期报告 | 2024-09-17 |
| 2024-09-20 | 36634.14 | 未披露 | 定期报告 | 2024-08-31 |
| 2024-05-13 | 36456.70 | 未披露 |
更多>>
From January 1, 2024 to March 31, 2024
Exercise of share option
Reclassification of vesting of restricted share units
|
2024-03-31 |
| 2024-03-19 | 36382.21 | 未披露 |
更多>>
From December 31,2022 to December 31,2023
Issuance of ordinary shares relating to private placement for institutional investors, net of issuance costs
Issuance of ordinary shares relating to registered direct offering, net of issuance costs
Issuance of ordinary shares relating to the exercise of warrant
|
2023-12-31 |
| 2023-08-21 | 36457.68 | 未披露 | 定期报告 | 2023-08-18 |
| 2023-08-15 | 36271.23 | 未披露 | 定期报告 | 2023-06-30 |
| 2023-05-26 | 36070.14 | 未披露 | 定期报告 | 2023-05-19 |
| 2023-05-26 | 33092.91 | 未披露 | 定期报告 | 2023-03-31 |
| 2023-03-30 | 33013.45 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of ordinary shares for follow-on public offering, net of issuance costs
|
2022-12-31 |
| 2022-09-16 | 33480.56 | 未披露 | 定期报告 | 2022-09-13 |
| 2022-07-29 | 32574.17 | 未披露 |
更多>>
1.ADSs offered by 8,140,000 ADSs.
2.The number of ordinary shares that will be outstanding immediately after this offering is based on 309,461,684 ordinary shares outstanding as of March 31, 2022
|
2022-07-29 |
| 2022-07-25 | 30946.17 | 未披露 | 定期报告 | 2022-03-31 |
| 2022-03-31 | 30845.69 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of ordinary shares relating to private placement for an institutional investor
Issuance of ordinary shares for follow-on public offering, net of issuance costs
Exercise of share options
Reclassification of vested restricted stock units
|
2021-12-31 |
| 2021-12-20 | 30566.18 | 未披露 |
更多>>
1.ADSs offered by company 7,500,000 ADSs.
2.The number of ordinary shares that will be outstanding immediately after this offering is based on 290,661,844 ordinary shares outstanding as of September 30, 2021.
|
2021-12-20 |
| 2021-12-14 | 29066.18 | 未披露 | 定期报告 | 2021-09-30 |
| 2021-08-23 | 28942.81 | 未披露 |
更多>>
From January 1, 2021 to June 30, 2021
Issuance of ordinary shares relating to private placement for an institutional investor
|
2021-06-30 |
| 2021-07-01 | 28926.41 | 未披露 | 定期报告 | 2021-05-31 |
| 2021-07-02 | 26647.62 | 未披露 | 定期报告 | 2021-03-31 |
| 2021-04-02 | 26601.03 | 未披露 |
更多>>
from December 31, 2019 to December 31, 2020
Conversion of convertible redeemable preferred shares to ordinary shares
Issuance of ordinary shares for initial public offering, net of issurance costs
Issuance of ordinary shares relating to private placement by Genscript
Exercise of share options
|
2020-12-31 |
| 2020-06-08 | 25848.51 | 未披露 |
更多>>
1.ADSs offered by us 18,425,000 ADSs.
2.The number of ordinary shares that will be issued and outstanding immediately after this offering is based on the 220,591,629 ordinary shares outstanding prior to giving effect to this offering, which consists of 200,000,000 ordinary shares outstanding as of March 31, 2020
|
2020-06-05 |
| 2018-07-09 | 1602.96 | 未披露 | 定期报告 | 2018-07-09 |
From December 31, 2023 to December 31, 2024
Reclassification of vested restricted share units
From January 1, 2024 to September 30, 2024
Reclassification of vested restricted share units
From January 1, 2024 to March 31, 2024
Exercise of share option
Reclassification of vesting of restricted share units
From December 31,2022 to December 31,2023
Issuance of ordinary shares relating to private placement for institutional investors, net of issuance costs
Issuance of ordinary shares relating to registered direct offering, net of issuance costs
Issuance of ordinary shares relating to the exercise of warrant
From December 31, 2021 to December 31, 2022
Issuance of ordinary shares for follow-on public offering, net of issuance costs
1.ADSs offered by 8,140,000 ADSs.
2.The number of ordinary shares that will be outstanding immediately after this offering is based on 309,461,684 ordinary shares outstanding as of March 31, 2022
From December 31, 2020 to December 31, 2021
Issuance of ordinary shares relating to private placement for an institutional investor
Issuance of ordinary shares for follow-on public offering, net of issuance costs
Exercise of share options
Reclassification of vested restricted stock units
1.ADSs offered by company 7,500,000 ADSs.
2.The number of ordinary shares that will be outstanding immediately after this offering is based on 290,661,844 ordinary shares outstanding as of September 30, 2021.
From January 1, 2021 to June 30, 2021
Issuance of ordinary shares relating to private placement for an institutional investor
from December 31, 2019 to December 31, 2020
Conversion of convertible redeemable preferred shares to ordinary shares
Issuance of ordinary shares for initial public offering, net of issurance costs
Issuance of ordinary shares relating to private placement by Genscript
Exercise of share options
1.ADSs offered by us 18,425,000 ADSs.
2.The number of ordinary shares that will be issued and outstanding immediately after this offering is based on the 220,591,629 ordinary shares outstanding prior to giving effect to this offering, which consists of 200,000,000 ordinary shares outstanding as of March 31, 2020